ELETRIPTAN HYDROBROMIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Eletriptan Hydrobromide, and when can generic versions of Eletriptan Hydrobromide launch?
Eletriptan Hydrobromide is a drug marketed by Annora Pharma, Aurobindo Pharma, Carlsbad, Chartwell Rx, Mylan, Regcon Holdings, Stevens J, Teva Pharms Usa, and Zydus Pharms. and is included in nine NDAs.
The generic ingredient in ELETRIPTAN HYDROBROMIDE is eletriptan hydrobromide. There is one drug master file entry for this compound. Eleven suppliers are listed for this compound. Additional details are available on the eletriptan hydrobromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eletriptan Hydrobromide
A generic version of ELETRIPTAN HYDROBROMIDE was approved as eletriptan hydrobromide by ZYDUS PHARMS on June 16th, 2017.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ELETRIPTAN HYDROBROMIDE?
- What are the global sales for ELETRIPTAN HYDROBROMIDE?
- What is Average Wholesale Price for ELETRIPTAN HYDROBROMIDE?
Summary for ELETRIPTAN HYDROBROMIDE
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 9 |
| Finished Product Suppliers / Packagers: | 10 |
| Raw Ingredient (Bulk) Api Vendors: | 67 |
| Clinical Trials: | 2 |
| Patent Applications: | 503 |
| DailyMed Link: | ELETRIPTAN HYDROBROMIDE at DailyMed |
Recent Clinical Trials for ELETRIPTAN HYDROBROMIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| VectorB2B | PHASE1 |
| Technophage, SA | PHASE1 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 1 |
Pharmacology for ELETRIPTAN HYDROBROMIDE
| Drug Class | Serotonin-1b and Serotonin-1d Receptor Agonist |
| Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for ELETRIPTAN HYDROBROMIDE
Paragraph IV (Patent) Challenges for ELETRIPTAN HYDROBROMIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| RELPAX | Tablets | eletriptan hydrobromide | 20 mg and 40 mg | 021016 | 1 | 2010-03-29 |
US Patents and Regulatory Information for ELETRIPTAN HYDROBROMIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annora Pharma | ELETRIPTAN HYDROBROMIDE | eletriptan hydrobromide | TABLET;ORAL | 219143-001 | Jul 7, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Zydus Pharms | ELETRIPTAN HYDROBROMIDE | eletriptan hydrobromide | TABLET;ORAL | 206409-002 | Jun 16, 2017 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Chartwell Rx | ELETRIPTAN HYDROBROMIDE | eletriptan hydrobromide | TABLET;ORAL | 205186-001 | Aug 29, 2017 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
